This is an old revision of the document!
====== Rheumatology ======Inflammatory & autoimmune disease pharmacology
This section organizes rheumatologic therapy by immune pathway, drug class, and clinical use.Start with foundational immunology, then move to drug classes and disease‑specific protocols.
—-===== Quick Start ===== * Foundations: Immunology Physiology · Histamine / Hypersensitivity · Eicosanoids (NSAIDs & Leukotrienes) * Core classes: Conventional DMARDs · Biologic DMARDs · JAK/Targeted Therapies · Glucocorticoids * Key diseases: Rheumatoid Arthritis · Psoriatic Arthritis · Ankylosing Spondylitis · Systemic Lupus (SLE) · Gout—-===== Drug Classes ========= Conventional DMARDs ==== * Methotrexate * Hydroxychloroquine * Sulfasalazine * Leflunomide==== Biologic DMARDs ==== * TNF inhibitors (adalimumab, etanercept, infliximab, etc.) * IL‑6 inhibitors (tocilizumab, sarilumab) * IL‑17 inhibitors (secukinumab, ixekizumab) * IL‑12/23 inhibitors (ustekinumab) * B‑cell depletion (rituximab) * T‑cell co‑stimulation (abatacept) * Complement inhibitors (eculizumab)==== Targeted Small Molecules ==== * JAK inhibitors (tofacitinib, baricitinib, upadacitinib) * PDE4 inhibitors (apremilast) * Other targeted agents==== Glucocorticoids ==== * Systemic steroids * Local / intra‑articular—-===== Disease‑Specific Pathways ===== * Rheumatoid Arthritis (RA) * Psoriatic Arthritis (PsA) * Ankylosing Spondylitis / AxSpA * Systemic Lupus Erythematosus (SLE) * Vasculitides * Inflammatory Myopathies * Giant Cell Arteritis * Sjögren Syndrome—-===== Monitoring & Safety ===== * Baseline & ongoing monitoring * Infection risk & vaccines * Pregnancy & lactation considerations * TB / Hep B screening—-===== Pearls & Tables ===== * Clinical pearls * Mechanism → adverse effect tables * Head‑to‑head comparisons